Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03226119 · ClinicalTrials.gov registry record · Phase 4
MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study
A Phase 4 study of HTLV-I Infections and HTLV-II Infections, sponsored by MP Biomedicals.
- Completed
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
- 3
- Study locations
NCT03226119 is a Phase 4 study of HTLV-I Infections and HTLV-II Infections that has completed, run by MP Biomedicals. The registered enrollment target is 150 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT03226119, a Phase 4 study of HTLV-I Infections and HTLV-II Infections, has completed, sponsored by MP Biomedicals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
- 3
- Study locations
Study Summary
This post-market study is intended to assess the performance of the HTLV Blot 2.4 in repository serum/plasma specimens with neurological disorders (n=100) or an HTLV known positive infection (n=50).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST MP Diagnostics HTLV Blot 2.4
Study Locations (3)
Pennsylvania
- LABS, Inc. - Philadelphia
Texas
- Qualtex Laboratories - San Antonio
Virginia
- Eastern Virginia Medical School (EVMS) - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2018-01-15 |
| Est. Completion | 2018-08-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03226119
The ClinicalTrials.gov registry entry for NCT03226119 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MP Biomedicals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with HTLV-I Infections appearing as the primary indexed condition, and to 1 intervention - of which MP Diagnostics HTLV Blot 2.4 is the first listed.
NCT03226119 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Pennsylvania, Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT03226119 about?
NCT03226119 is a clinical study titled "MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study". This post-market study is intended to assess the performance of the HTLV Blot 2.4 in repository serum/plasma specimens with neurological disorders (n=100) or an HTLV known positive infection (n=50).
What is the current status of trial NCT03226119?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2018-01-15. Estimated completion is 2018-08-31.
What conditions does trial NCT03226119 study?
This clinical trial studies the following conditions: HTLV-I Infections, HTLV-II Infections, Human T-lymphotropic Virus 1, Human T-lymphotropic Virus 2, HTLV I Associated T Cell Leukemia Lymphoma.
What interventions are being tested in trial NCT03226119?
The interventions under investigation include: MP Diagnostics HTLV Blot 2.4 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03226119?
This trial is sponsored by MP Biomedicals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03226119 being conducted?
This trial has 3 study locations across Pennsylvania, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.